Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol)
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Therapeutic target
研究概览
简要总结
It remains unknown if the association between moderate to low intensity statin therapy and ezetimibe and nutraceuticals might have a therapeutic role in high-intensity statin intolerant patients
详细描述
The aim of this study will be to evaluate whether the association between statin and exetimibe vs statin + ezetimibe + nutraceuticals can lead to higher percentage of LDL target achievement
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with angiographically assessed diagnosis of coronary artery disease
排除标准
- 未提供
研究组 & 干预措施
statin + ezetimibe
Low dose statin associated with ezetimibe
干预措施: statin + ezetimibe (Drug)
statin + ezetimibe
Low dose statin associated with ezetimibe
干预措施: statin + ezetimibe + Nutraceuticals (Drug)
statin + ezetimibe + Nutraceuticals
Low dose statin associated with ezetimibe and Nutraceuticals
干预措施: statin + ezetimibe (Drug)
statin + ezetimibe + Nutraceuticals
Low dose statin associated with ezetimibe and Nutraceuticals
干预措施: statin + ezetimibe + Nutraceuticals (Drug)
结局指标
主要结局
Therapeutic target
时间窗: Up to 3 months
LDL cholesterol \< 70 mg/dl
次要结局
未报告次要终点
研究者
Francesco Pelliccia
Assistant Professor
University of Roma La Sapienza